Pharmion

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...zyme Receives FDA Certification for Mozobil II-40 Celgene's Thalidomide pharmion Receives Marketing Authorization II-41 Ziopharm Commences Phase II Clin...eement with Seattle Genetics II-51 Celgene Agrees to Acquisition of pharmion II-51 PerkinElmer Plans Acquisition of ViaCell II-51 Favrille Annou...

Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors

... and pharmaceutical executive management experience. He was the founder of pharmion Corporation and served as its President and CEO from its inception through its acquisition eight years later. Under Mr. Mahaffy's leadership, pharmion successfully acquired, developed and gained approval for several oncology p...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...edicis Pharmaceutical (NYSE: MRX ) Mentor Corp. (NYSE: MNT ) ONYX Pharmaceuticals Inc. (Nasdaq: ONXX ) PDL BioPharma, Inc. (Nasdaq: PDLI ) pharmion Corp. (Nasdaq: PHRM ) Progenics Pharmaceuticals Inc. (Nasdaq: PGNX ) Regeneron Pharmaceuticals (Nasdaq: REGN ) Respironics Inc. (Nasdaq: RES...

QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes

...ISIS Pharmaceuticals (Nasdaq: ISIS ) will replace pharmion Corp. (Nasdaq: PHRM ) in the HealthShares(TM) Com...harmaceuticals Corp. (Nasdaq: SNTA ) will replace pharmion Corp. (Nasdaq: PHRM ) in the Cancer Index. pharmion is being acquired by Celgene Corp. (Nasdaq: CELG ...

Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting

...nders ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) and MethylGene Inc (T...n Atlanta. "This study demonstrates the progress pharmion has made in advancing the clinical development of ...favorably influence the clinical course of cancer. pharmion strongly believes that by targeting two separate e...

Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

...eeting ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM) today announced final d...65 years with newly-diagnosed multiple myeloma." pharmion submitted an application to the European Medicines...arketing authorization application for Thalidomide pharmion in combination with melphalan and prednisone as fi...

Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting

...tients ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TS...rcent of newly-diagnosed cases. About Pharmion pharmion is a leading global oncology company uniquely focu...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting

... BOULDER, Colo., Dec. 6 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) reported today that d...rs, Pharmion's newest epigenetic research program. pharmion currently markets Vidaza, the parenteral formulati...he MRC IX Study (Abstract 3593). About Pharmion pharmion is a leading global oncology company uniquely focu...

Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial

...PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) and GPC Biotech AG (F...h. "We are currently discussing with our partners, pharmion and Yakult, plans for the future development of sa...data could be submitted during the review process. pharmion plans to review the additional analyses and work c...

GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial

...ciated with the development and regulatory filings of Satraplatin. GPC Biotech has license agreements with Pharmion GmbH, a wholly owned subsidiary of pharmion Corporation, and Yakult Honsha Co., Ltd. Spectrum licensed worldwide rights to Satraplatin from Johnson Matthey PLC. About Spectrum Pharmaceuticals ...

Pharmion in Medical Technology

Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia

...ions and stem cell transplants. About Pharmion pharmion is a leading global oncology company focused on ac...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...es. Additional risks and uncertainties relating to pharmion and its business can be found in the "Risk Factors...

Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia

...ions and stem cell transplants. About Pharmion pharmion is a leading global oncology company focused on ac...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...es. Additional risks and uncertainties relating to pharmion and its business can be found in the "Risk Factors...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

... BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today announced that ...ng authorization application (MAA) for Thalidomide pharmion was submitted to the EMEA in January 2007. The E...single marketing authorization would be granted to pharmion to market Thalidomide Pharmion for first line mult...

Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

... BOULDER, Colo., Jan. 14 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today announced the s...d with Vidaza should not nurse. About Pharmion pharmion is a leading global oncology company uniquely focu...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

...favorably influence the clinical course of cancer. pharmion strongly believes that by targeting two separate e...d with Vidaza should not nurse. About Pharmion pharmion is a leading global oncology company uniquely focu...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule

...eting ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today announced inter...d with Vidaza should not nurse. About Pharmion pharmion is a leading global oncology company uniquely focu...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

... BOULDER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today released interi...bicin is expected to complete by the end of 2007. pharmion has an additional ongoing Phase 2 study of Amrubic...is study are expected in the second half of 2008. pharmion recently initiated an international pivotal Phase ...

Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference

...of the study will enroll up to 40 patients. About pharmion pharmion is a leading global oncology company focused on ac...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer

... BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today announced the i...e rate, duration of response and quality of life. pharmion has completed the Scientific Advice (SA) process w...se 2 study in second-line sensitive SCLC patients, pharmion has two additional ongoing Phase 2 studies of amru...

Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors

...cutive vice president and chief medical officer of pharmion Corporation. "Cytotoxic chemotherapies such as Tax...A) for the treatment of Hodgkin's lymphoma. About pharmion pharmion is a leading global oncology company focused on ac...

Pharmion in Biological Technology

ISS Recommends Pharmion Shareholders Vote for Merger With Celgene

All Four Leading Independent Proxy Advisory Firms Recommend Pharmion stockholders vote FOR merger with Celgene Special Meeting of Shareholders Scheduled For March 6, 2008 Pharmion Corp. Urges All Shareholders to Vote FOR the Proposed Merger BOULDER, Colo., Feb. 26 /PRNe...

Sangart, Inc. Announces Key Executive Appointments and Company Restructuring

...all biotech companies on overall branding and commercialization. Prior to Sangart, he was Senior Director of International Marketing for pharmion Ltd. -- Kristine Figueroa, CCP, Head of Human Resources -- Ms. Figueroa is responsible for all human resources for the company, including ...

EntreMed Reports Third Quarter 2008 Financial Results

...of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earli...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)

...) Medicis Pharmaceutical (NYSE: MRX ) Mentor Corp. (NYSE: MNT ) ONYX Pharmaceuticals Inc. (Nasdaq: ONXX ) PDL BioPharma, Inc. (Nasdaq: PDLI ) pharmion Corp. (Nasdaq: PHRM ) Progenics Pharmaceuticals Inc. (Nasdaq: PGNX ) Regeneron Pharmaceuticals (Nasdaq: REGN ) Respironics Inc. (Nasdaq: RESP )...

Pharmion Corporation Announces 2007 Operating Results

... BOULDER, Colo., Feb. 19 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today reported financ...d oral Azacitidine." 2007 Financial Highlights pharmion reported a net loss of $(63.9) million, or $(1.81)...tic syndromes patients. As of December 31, 2007, pharmion had $248.5 million in cash, cash equivalents and s...

EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes

... BOULDER, Colo., Feb. 7 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) today announced that ...d with Vidaza should not nurse. About Pharmion pharmion is a leading global oncology company focused on ac...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

Biotech Survives Market Turbulence in November

...raditional consumer 'Black Friday' spree," noted Burrill. Celgene Corp. vaulted itself into biotech's top five by market cap with its acquisition of pharmion Corp. for $2.9 billion in cash and stock. The move is part of its drive to become a major global player in developing and marketing blood-cancer drugs...

Pharmion Corporation to Announce Third Quarter 2007 Financial Results

... BOULDER, Colo., Oct. 18 /PRNewswire-FirstCall/ -- pharmion Corporation (Nasdaq: PHRM ) will announce its thi...e, Street Events ( http://www.streetevents.com ). pharmion is a leading global oncology company focused on ac...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...

Accera, Inc. Names William T. Poncy Vice President of Commercial Development

...cial organization and launched a pulmonary anti-hypertension franchise. Previously he was the North American vice president of sales and marketing for pharmion Corp., where he developed an oncology commercial organization. He has also held positions in sales, managed care, trade, marketing and various managem...

Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma

...our website at http://www.methylgene.com . About pharmion pharmion is a leading global oncology company focused on ac...U.S., Europe and additional international markets. pharmion has a number of products on the market including t...